The US Drug Enforcement Administration (DEA) is being subjected to yet another legal challenge over how they have managed the cannabis rescheduling process.
Doctors for Drug Policy Reform (D4DPR), an alliance representing over 400 physicians, is the latest organization to accuse the Drug Enforcement Administration (DEA) of bias towards cannabis reform.
Now the group has mounted legal challenges against the administration by filing a 56-page brief with the US Court of Appeals for DC Circuit on Monday, February 17 requesting to have its selection process reconsidered.
Legal action taken by D4DPR alleges that the Drug Enforcement Administration acted arbitrarily by restricting participation at their hearing – now postponed indefinitely – while rejecting out of 163 applicants 138 outright.
As well, they deemed the process opaque by not providing an explanation as to why certain participants were chosen over others and why most participants opposed rescheduling of classes.
If D4DPR’s appeal succeeds and selection process needs to be redone, cannabis rescheduling would only become further delayed.
Cannabis advocates continue to assess the Trump administration’s stance on cannabis use within the US, with another anti-cannabis DEA administrator announced last week.
According to Benzinga’s interview with former Republican congressman Adam Kinzinger, there appears to be an expanding chasm within the GOP on matters related to drug policy.
Kinzinger noted a faction within this “new Republican Party that is very hardline anti-drug”, such as those associated with Reagan-era prohibitionism policies. But there was also an emerging libertarian wing supporting cannabis and psychedelic reform policies; an important divide in future US drug policies.
Kinzinger holds that federal cannabis legalization is inevitable and predicts either full legalization or decriminalization will come about within 10 years.
The United States Drug Enforcement Administration (DEA) is facing another legal challenge over how it has implemented cannabis rescheduling processes.
Doctors for Drug Policy Reform (D4DPR), an organisation representing over 400 physicians, has joined other critics in accusing the Drug Enforcement Agency (DEA) of discrimination against cannabis reform efforts.
Now the group has taken legal action against the administration by filing a 56-page brief with the US Court of Appeals for DC Circuit on Monday, February 17 requesting to have its selection process redone.
Legal challenge brought against the Drug Enforcement Agency by D4DPR alleges that its decision to limit participants at a hearing, currently postponed until further notice, while rejecting out of 163 applicants was arbitrary and unacceptable.
Further, they characterized the process as opaque, as there was no explanation provided as to why certain participants were chosen over others and why most opposed any reschedulement attempts.
If D4DPR’s appeal succeeds and selection process needs to be revised, cannabis rescheduling would become even more complex and would only add delay and frustration on an already difficult journey.
As cannabis advocates continue to assess the Trump administration’s position on cannabis use in America, with yet another anti-cannabis DEA administrator being announced, last week was no different in that respect.
Recent reporting by Benzinga citing former Republican congressman Adam Kinzinger shows a widening chasm within the GOP over drug policy issues.
“Within this new Republican Party is an anti-drug faction which adheres to Reagan-era prohibitionist policies.” However, Kinzinger also noted a rising libertarian faction which supports cannabis and psychedelic reform; an influencer which could shape future US drug policies.
Kinzinger believes federal cannabis legalization will ultimately take place, with decriminalization happening either simultaneously or shortly within this decade.
Read About Cannabis Law Resources in Poland Here
Discover essential legal pages on cannabis cultivation, sales and medical product regulations in Poland. These resources will guide you through permissions, certifications and compliance requirements.
Polish News Registration and Interests of Cannabis Businesses
Permits have been obtained for cannabis sales in Poland.
Authorization to import or manufacture medical products.
Medical Product Manufacture and Import License Application Form.
Good Manufacturing Practices (GMP) Certification.
Registration of Pharmaceutical products in Poland.